【齐心抗疫】NEJM：吉利德公司的瑞德西韦对新冠病毒最有效

Cresarea

Antiviral Drug Remdesivir By Gilead:Most Effective For Treating 2019-nCoV Coronavirus According To Study Trials Published Last Week In NEJM Journal
新英格兰医学杂志：吉利德公司的瑞德西韦对新冠病毒最有效

Source: Thailand Medical News  Feb 02, 2020
来源：泰国医学新闻 2020年2月2日

Already at the start of the coronavirus outbreak in late December 2019, Chinese medical researchers and doctors were already treating coronavirus infected patients with a HIV antiviral called Aluvia, also known as Kaletra, which is a combination of lopinavir and ritonavir and is produced by pharmaceutical company AbbVie. (simply goggle online and you can see that many medical sites were already talking about the usage of this drug for coronavirus since early January 2020.)
早在2019年12月底新型冠状病毒爆发伊始，中国的医疗研究人员和医生就开始使用克力芝（一种用于对抗艾滋病病毒的药物Aluvia，又叫Kaletra）来治疗受感染的病人，该药物由洛匹那韦（lopinavir）和利托那韦（ritonavir）组成，由美国的制药企业艾伯维公司（AbbVie）生产。（只需在网上浏览一下，你就会发现自2020年1月初以来，许多医疗网站已经在讨论这种用于对抗新型冠状病毒药物的使用方法。）
The antivirals were the first choice as there was already more than 37 previous published clinical studies that showed it was effective for the SARS coronavirus and since the 2019-nCoV coronavirus was similar to the SARS coronavirus (initial gene sequencing had shown a 84 to 87 percent match), it was the first choice.
之前，已有超过37项发表的临床研究报告表明，某些抗病毒药物能够有效治疗SARS，而新型冠状病毒与SARS冠状病毒类似（最初的基因测序也表明这两种冠状病毒有着84%-87%的相似性）。因而我们可以认为这些抗病毒药物是应对新型冠状病毒的首选。

The Chinese doctors also experimented with other combo protocols using the HIV antivirals along with influenza antivirals such as oseltamivir phosphate (available as a generic version or under the trade name Tamiflu®), zanamivir (trade name Relenza®), peramivir (trade name Rapivab®)  and baloxavir marboxil (trade name Xofluza®).
同时，中国医生还对联合使用抗HIV病毒和抗流感病毒药物的方案进行了试验，这些药物包括磷酸奥司他韦（oseltamivir phosphate）[有非注册商标的药物和品牌药达菲（Tamiflu）
]、扎那米韦（zanamivir，商标名Relenza）、帕拉米韦（peramivir，商标名Rapivab）还有巴洛沙韦（baloxavir marboxil，商标名Xofluza）。

However the Chinese doctors found that the drug combinations were not effective especially in patients in serious stages as it aggravated their kidney functions and lead to kidney failure and even accelerated the organ failure conditions they were already experiencing in the latent stages of the disease.
然而，有中国医生发现联合用药尤其是在重症患者身上收效甚微。这是因为联合用药会破坏患者的肾功能，导致肾功能衰竭，更严重的是，这还可能会加重患者在疾病潜伏期就已有的器官衰竭的病症。

Later an adopted protocol was to take two standard doses of lopinavir and ritonavir along with a dose of nebulized alpha-interferon twice a day. Using this protocol, more than 230 patients were cured according to Guizhou Medical University in China.
之后采用的一种方案是服用两倍标准剂量的洛匹那韦和利托那韦，同时雾化吸入一剂量的α-干扰素，每天用药两次。贵州医科大学的实验表明，230多名患者在经过该方案治疗之后都痊愈了。

However, Gilead Pharma had another more effective antiviral drug candidate called remdesivir which is actually a nucleotide analog prodrug. The company shipped stocks to the Chinese as early as mid-January 2020 for testing.
但是，吉利德制药公司还有另一种更有效的抗病毒候选药——瑞德西韦，该药实际上是一种类似核苷酸的前体药物。早在2020年1月中旬，该公司就将一大批瑞德西韦海运至中国进行实验研究。

Gilead also started laboratory testing of remdesivir against 2019-nCoV. In those studies, Gilead stated that remdesivir was also "shown to be active" against SARS and MERS in animals.
与此同时，吉利德公司还对瑞德西韦的抗新型冠状病毒性进行了实验。吉利德公司声称，这些实验研究表明瑞德西韦对动物体内的SARS病毒和MERS（中东呼吸综合征）病毒“显示出活跃的抗病毒性”。
The drug was administered to the first US patient confirmed with the 2019-nCoV coronavirus since the 22nd of January for "compassionate use" after he progressed to pneumonia.(this was done with USFDA and CDC support and approvals)
自1月22日以来，美国首例确诊感染新型冠状病毒的患者在得肺炎之后，出于“同情用药，得到了该药的治疗。（该用药是在美国食品和药品监督管理局（USFDA）和美国疾病预防与控制中心（CDC）支持和批准下进行的）

The patient has since recovered and the findings of that drug trial have been published in The New England Journal of Medicine since the 31st of January 2020.
自那之后，该患者就基本痊愈了。2020年1月31日，新英格兰医学杂志发表了该药物试验的结果。

Meanwhile since the late January 2020, Chinese medical researchers stated to the media that in exploratory research considering a selection of 30 drug candidates, three of them, remdesivir, chloroquine and lopinavir/ritonavir, seemed to have "fairly good inhibitory effects" on 2019-nCoV at the cellular level. Requests to start clinical testing were submitted along with that for remdesivir.
与此同时，中国医学研究人员向媒体表示，2020年1月下旬，在对30种候选药物进行探索性试验的过程中他们发现，其中的三种，包括瑞德西韦、氯喹、以及洛匹那韦/利托那韦，似乎都在细胞层面上对新型冠状病毒有“相对良好的抑制作用”。研究人员已经递交了针对瑞德西韦开展临床试验的请求。

The American trial and also subsequent Chinese trials all indicate that it is the current drug choice for treatment. Gilead is planning further trial and also to get the drug repurposed for 2019n-CoV treatment with the US FDA.
美国研究人员所进行的试验以及随后中国研究人员进行的试验都表明，瑞德西韦是目前治疗的用药选择。吉利德公司计划对瑞德西韦开展进一步的试验，并取得美国食品和药品监督管理局的认证，将该药用于治疗新型冠状病毒感染。

The public is to be aware and there are some South-east Asian entities claiming to have invented the cure for the 2019-nCoV or have invented these drugs and these protocols and some of this claims have been published in unreliable media with journalist that are totally ignorant of medical matters. The same also goes about allegations of certain doctors in South-east Asia who had discovered the MERS virus first, this is not true and the same goes about them discovering the new coronavirus before the Chinese or others, even in terms of genomic mapping.)
公众应注意到，有几家东南亚的公司宣称他们已经研究出了用于治疗新型冠状病毒的疗法或是与此相关的药物或治疗方案。某些不靠谱的媒体发表了这样的声明，而这些媒体记者却完全忽视了医疗问题。而同样的情况也发生在某些东南亚医生的声明上，他们声称最先发现了MERS病毒，这当然是假的。他们同样还声称，在中国人员或其他国家人员之前就已经发现了新型冠状病毒，甚至是测出了病毒的基因组图谱。


翻译by纸鸢翻译社-Fedex
校对by旺仔
树屋字幕组-文翻组&纸鸢翻译社合作出品
文章来源：
https://www.thailandmedical.news ... eek-in-nejm-journal
翻译仅供学习交流，严禁用于商业用途
文章观点不代表树屋字幕组-文翻组&纸鸢翻译社的观点
本文版权归原作者及Thailand Medical News所有

ljs610330@sina.

好消息。谢谢。

joooo99

如果有很好的效果，真是太好了